The clinical application of metformin in children and adolescents: A short update

Main Article Content

Ashraf Soliman
Vincenzo De Sanctis
Nada Alaaraj
Noor Hamed


Metformin, insulin resistance, prediabetes, type 2 diabetes mellitus, premature pubarche, polycystic ovary syndrome


Summary. Metformin is a widely used drug that results in clear benefits in relation to glucose metabolism and diabetes-related complications. The global increase in the prevalence of obesity among children and adolescents is accompanied by the appearance and increasing prevalence of insulin resistance, prediabetes, and type 2 diabetes mellitus (T2DM). In addition, children, and adolescents with premature pubarche and polycystic ovary have considerable degree of insulin resistance. The insulin sensitizing actions of metformin encouraged many investigators and physician to use it as the key drug in these conditions for both prevention and treatment. However, long term-controlled studies are still required to assess the degree and duration of effectiveness and safety of using metformin. This review tries to update physicians about the main and the new therapeutic perspectives of this drug.



Download data is not yet available.


Metrics Loading ...
Abstract 26 | PDF Downloads 8


1. American Diabetes Association.Standards of medical care in diabetes--2009. Diabetes Care.2009: 32 Suppl 1: S13-61.
2. Patade GR, Marita AR.Metformin: A Journey from countryside to the bedside. J ObesMetab Res.2014; 1:127-130.
3. Sterne J.Du nouveau dans les antidiabetiques.La NN dimethylamineguanylguanide (N.N.D.G.) (The newantidiabetic NNdimethylamineguanylguanide). Maroc Med.1957;36: 1295-1296.
4. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017; 60: 1577‐1585.

5. Zilov AV, Abdelaziz SI, AlShammary A, et al. Mechanisms of action of metformin with special reference to cardiovascular protection. Diabetes Metab Res Rev. 2019;35(7):e3173. doi:10.1002/dmrr.3173.
6. Wu T, Xie C, Wu H, Jones KL, Horowitz M, Rayner CK. Metformin reduces the rate of small intestinal glucose absorption in type 2 diabetes. Diabetes Obes Metab. 2017;19:290‐293..
7. Bristol-Myers .U.S. Food and Drug Administration. Glucophage (metformin hydrochloride tablets) Label Squibb Information; August 27, 2008.
8. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics.2012; 22: 820-827.
9. Gormsen LC, Sundelin EI, Jensen JB, et al. In vivo imaging of human 11C-metformin in peripheral organs: dosimetry, biodistribution, and kinetic analyses. J Nucl Med. 2016;57:1920–1926.
10. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81–98.
11. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30:359-371.
12. Thomas I, Gregg B. Metformin; a review of its history and future: from lilac to longevity, Pediatr Diabetes, 2017;18:10–16.
13. Foretz M, Guigas Biollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol.2019;15: 569–589.
14. Yamaguchi S, Katahira H, Ozawa S, Nakamichi Y, Tanaka T, et al. Activators of AMP-activated protein kinase enhance GLUT4 translocation and its glucose transport activity in 3T3-L1 adipocytes. Am J Physiol Endocrinol Metab.2005;289:643-649.
15. Bogachus LD, Turcotte LP.Genetic downregulation of AMPK-alpha isoforms uncovers the mechanism by which metformin decreases FA uptake and oxidation in skeletal muscle cells. Am J Physiol Cell Physiol.2010; 299:1549- 1561.
16. Saeedi R, Parsons HL, Wambolt RB, Paulson K, Sharma V, et al.Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms. Am J Physiol Heart Circ Physiol.2008; 294: 2497-2506.
17. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016; 59:426–435.
18. Forslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015;528:262–266.

19. Copeland KC, Silverstein J, Moore KR, et al. American Academy of Pediatrics. Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents. Pediatrics. 2013; 131:364-382.
20. Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith GJ.Type 2 diabetes in children and adolescents. Pediatr Diabetes.2009;10 (Suppl 12):17-32.

21. McDonagh MS, Selph S, Ozpinar A, Foley C. Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger. JAMA Pediatr. 2014;168:178‐184.
22. American Diabetes A. Children and Adolescents: Standards of Medical Care in Diabetes-2018. Diabetes Care.2018;41(Suppl 1):S126-S36.
23. Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007;30:790-794.
24. Bodmer M, Meier C, Krähenbühl JSS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31:2086–91.
25. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consen sus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
26. Hur KY, Kim MK, Ko SH, et al. Metformin Treatment for Patients with Diabetes and Chronic Kidney Disease: A Korean Diabetes Association and Korean Society of Nephrology Consensus Statement. Diabetes Metab J. 2020;44:3‐10.
27. Canadian Diabetes Association (CDA) Clinical Practice Guideline Pharmacologic Management of Type 2 Diabetes. CDA website. 13
28. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a sys tematic review. JAMA. 2014;312;2668-2675.
29. Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754‐1761.
30. American Diabetes A. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1): S73-S85.
31. American Diabetes A. Classification and diagnosis of Diabetes: Standards of medical Care in Diabetes-2019. Diabetes Care. 2019;42:S13-S28.
32. RISE Consortium. Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care. 2018;41(8):1696‐1706.
33. RISE Consortium. Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: II. Observations Using the Oral Glucose Tolerance Test. Diabetes Care. 2018;41(8):1707‐1716.
34. Khokhar A, Umpaichitra V, Chin VL, Perez-Colon S. Metformin use in children and adolescents with Prediabetes. Pediatr Clin North Am. 2017;64:1341-1353.
35. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
37. Temneanu OR, Trandafir LM, Purcarea MR. Type 2 diabetes mellitus in children and adolescents: a relatively new clinical problem within pediatric practice. J Med Life.2016;9:235-239.
38. Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-term complications and mortality in young-onset diabetes: Type 2 diabetes is more hazardous and lethal than type 1 diabetes. Diabetes Care. 2013;36:3863–3869.
39. Zeitler, P, Arslanian, S, Fu, J, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth. Pediatr Diabetes. 2018;19 (Suppl. 27): 28– 46.
40. Copeland KC, Silverstein J, Moore KR, Prazar GE, Raymer T, et al. American Academy of Pediatrics. Management of newly diagnosed type 2 Diabetes Mellitus (T2DM) in children and adolescents. Pediatrics.2013;131: 364-382.
41. Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association. Diabetes Care. 2018;41:2648‐2668.
42. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: A randomized controlled trial. Diabetes Care. 2002;25:89-94.
43. Group TS, Zeitler P, Epstein L, et al. Treatment options for type 2 diabetes in adolescents and youth: A study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatric Diabetes. 2007;8:74-87.
44. TODAY Study Group, Zeitler P, Hirst K, Pyle L, Linder B, et al.A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med.2012; 366: 2247-2256.
45. Narashimhan S, Weinstock R. Youth-onset of type 2 diabetes mellitus: lessons learned from the TODAY Study. Mayo Clin Proc. 2014;89:806–816.

46. Kelsey MM, Geffner ME, Guandalini C, Pyle L, Tamborlane WV, Zeitler P, White Study Group. Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study. Pediatr Diabetes. 2016;17:212–221.
47. Bloomgarden ZT. Insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care 2005; 28: 1518-1523.
48. Levy-Marchal C, Arslanian S, Cutfield W, et al. Insulin resistance in children: Consensus, perspective, and future directions. J Clin Endocrinol Metabol.2010;95:5189–5198.
49. Arslanian S, Kim JY, Nasr A, et al. Insulin sensitivity across the lifespan from obese adolescents to obese adults with impaired glucose tolerance : who is worse off ? Pediatr Diabetes.2017; 19:205–211.
50. Ranucci C, Pippi R, Buratta L, et al. Effects of an Intensive Lifestyle Intervention to Treat Overweight/ Obese Children and Adolescents. Biomed Res Int. 2017;2017:8573725. doi:10.1155/2017/8573725.
51. Tagi VM, Giannini C, Chiarelli F. Insulin Resistance in Children. Front Endocrinol (Lausanne). 2019;10:342.doi:10.3389/fendo.2019.00342
52. Lentferink YE, Knibbe CAJ, van der Vorst MMJ. Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review. Drugs. 2018;78:1887‐1901
53. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50:1457‐1461.
54. Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006;91:2074‐2080.
55. Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2008;21:339‐348
56.Mead E, Atkinson G, Richter B, et al. Drug interventions for the treatment of obesity in children and adolescents. Cochrane Database Syst Rev. 2016;11(11):CD012436. Published 2016 Nov 29. doi:10.1002/ 14651858.CD012436.
57.Lentferink YE, Knibbe CAJ, van der Vorst MMJ. Efficacy of Metformin Treatment with Respect to Weight Reduction in Children and Adults with Obesity: A Systematic Review. Drugs. 2018; 78:1887–1901.
58.Bassols J, Martínez-Calcerrada JM, Osiniri I, et al. Effects of metformin administration on endocrine-metabolic parameters, visceral adiposity and cardiovascular risk factors in children with obesity and risk markers for metabolic syndrome: A pilot study. PLoS One. 2019;14(12):e0226303. doi:10.1371/ journal.pone.0226303.
59. Díaz M, Bassols J, López-Bermejo A, de Zegher F, Ibáñez L. Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo-controlled pilot study in prepubertal children. Pediatr Diabetes. 2015;16:538‐545.
60. Cardenas-Vargas E, Nava JA, Garza-Veloz I, et al. The Influence of Obesity on Puberty and Insulin Resistance in Mexican Children. Int J Endocrinol. 2018;2018:7067292. doi:10.1155/2018/7067292
61. Kelsey MM, Zeitler PS. Insulin Resistance of Puberty. Curr Diab Rep. 2016;16(7):64. doi:10.1007/ s11892-016-0751-5
62. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2014;37:2843‐2863.
63. Liu LL, Lawrence JM, Davis C, Liese AD, et al. , SEARCH for Diabetes in Youth Study Group.Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes. 2010;11:4-11.
64. Libman IM, Pietropaolo M, Arslanian SA, LaPorte RE, Becker DJ. Changing prevalence of overweight children and adolescents at onset of insulin-treated diabetes. Diabetes Care. 2003; 26:2871-2875.
65. Purnell JQ, Zinman B, Brunzell JD. The effect of excess weight gain with intensive diabetes mellitus treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes mellitus: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) Study. Circulation. 2013;127:180–187.
64. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010;53:809‐820.
67. Nadeau KJ, Chow K, Alam S, et al. Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study. Pediatr Diabetes. 2015;16:196‐203.
68. Abdelghaffar S, Attia AM. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev. 2009;(1):CD006691. Published 2009 Jan 21. doi:10.1002/ 14651858.CD006691.pub2

69. Liu W, Yang XJ. The Effect of Metformin on Adolescents with Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Int J Endocrinol. 2016;2016:3854071. doi:10.1155/ 2016/3854071.

70. Chiang JL, Maahs DM, Garvey KC, et al. Type 1 Diabetes in Children and Adolescents:A Position Statement by the American Diabetes Association. Diabetes Care. 2018;41:2026‐2044.
71. Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019;70:531‐544.
72. Newton KP, Hou J, Crimmins NA, et al. Prevalence of Prediabetes and Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease. JAMA Pediatr. 2016;170(10):e161971. doi:10.1001/jamapediatrics.2016.1971.
73. Corey KE, Vuppalanchi R, Vos M, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2015;60:360–367.
74. Utz-Melere M, Targa-Ferreira C, Lessa-Horta B, Epifanio M, Mouzaki M, Mattos AA. Non-Alcoholic Fatty Liver Disease in Children and Adolescents: Lifestyle Change – a Systematic Review and Meta-Analysis. Ann Hepatol. 2018;17:345-354.
75. Hung CK, Bodenheimer HC Jr. Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clin Liver Dis. 2018;22:175‐187.
76. Ozturk ZA, Kadayifci A. Insulin sensitizers for the treatment of non-alcoholic fatty liver disease. World J Hepatol. 2014;6:199‐206.
77. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012;2012:716404. doi:10.1155/2012/716404.
78. Jalali M, Rahimlou M, Mahmoodi M, et al. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2020;104799. doi:10.1016/j. phrs. 2020.104799.
79. Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2013;1:57-64.
80. Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and Management of Youth-Onset Type 2 Diabetes: A Position Statement by the American Diabetes Association. Diabetes Care. 2018;41:2648-2668.
81.Idkowiak J, Lavery GG, Dhir V, et al. Premature adrenarche: novel lessons from early onset androgen excess. Eur J Endocrinol. 2011;165:189-207.
82. Utriainen P, Laakso S, Liimatta J, Jääskeläinen J, Voutilainen R: Premature Adrenarche - A Common Condition with Variable Presentation. Horm Res Paediatr 2015;83:221-231.
83. Miller WL. The molecular basis of premature adrenarche: an hypothesis. Acta Paediatr Suppl. 1999;88:60–6.
84. Ibánez L, Ong KK, López-Bermejo A, Dunger DB, de Zegher F. Hyperinsulinaemic androgen excess in adolescent girls. Nat Rev Endocrinol. 2014;10(8):499-508.
85. Ibánez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab. 2006;91:2888–91.
86. Ibánez L, López-Bermejo A, Díaz M, Marcos MV, de Zegher F. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab. 2011;96:E1262–7.
87. Geller DH, Pacaud D, Gordon CM, Misra M; of the Drug and Therapeutics Committee of the Pediatric Endocrine Society. State of the Art Review: Emerging Therapies: The Use of Insulin Sensitizers in the Treatment of Adolescents with Polycystic Ovary Syndrome (PCOS). Int J Pediatr Endocrinol. 2011;2011(1):9. doi:10.1186/1687-9856-2011-9.
88. Ibáñez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. J Clin Endocrinol Metab. 2003;88:2600-2606.
89. Ibáñez L, Lopez-Bermejo A, Diaz M, Marcos MV, de Zegher F. Early metformin therapy to delay menarche and augment height in girls with precocious pubarche. Fertil Steril. 2011;95:727-730.
90. Ibáñez L, López-Bermejo A, Díaz M, Marcos MV, de Zegher F. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab. 2008;93:1841-1845.
91. Codner E, Iñíguez G, López P, et al. Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. Horm Res Paediatr. 2013;80:343–349.
92. Blank SK, Helm KD, McCartney CR, Marshall JC (2008) Polycystic ovary syndrome in adolescence. Ann N Y Acad Sci.2008 1135: 76-84.
93. Naz MSG, Tehrani FR, Majd HA, et al. The prevalence of polycystic ovary syndrome in adolescents: A systematic review and meta-analysis. Int J Reprod Biomed (Yazd). 2019;17:533-542.
94. Coviello AD, Legro RS, Dunaif A.Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab.2006; 91: 492-497.
95. Alemzadeh R, Kichler J, Calhoun M. Spectrum of metabolic dysfunction in relationship with hyperandrogenemia in obese adolescent girls with polycystic ovary syndrome. Eur J Endocrinol.2010; 162: 1093-1099.
96. Pau CT, Keefe C, Duran J, Welt CK. Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. J Clin Endocrinol Metab. 2014;99:1870-1878.
97. Bridger T, MacDonald S, Baltzer F, Rodd C. Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2006;160:241-246.
98. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzick DS. The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. J Clin Endocrinol Metab. 2008;93:4299-4306.
99. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab. 2002;87: 1555-1559.
100. Al Khalifah RA, Florez ID, Dennis B, Thabane L, Bassilious E. Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. Pediatrics. 2016;137(5):e20154089. doi:10.1542/peds.2015-4089
101. Lashen H. Role of metformin in the management of polycystic ovary syndrome. Ther Adv Endocrinol Metab. 2010;1:117–128.
102. Naderpoor N, Shorakae S, de Courten B, Misso ML, Moran LJ, Teede HJ. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis [published correction appears in Hum Reprod Update. 2016;22:408-409.
103. Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110:364-379.

Most read articles by the same author(s)

1 2 > >>